BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim HY, Hanrahan CF, Dowdy DW, Martinson NA, Golub JE, Bridges JFP. Priorities among HIV-positive individuals for tuberculosis preventive therapies. Int J Tuberc Lung Dis 2020;24:396-402. [PMID: 32317063 DOI: 10.5588/ijtld.18.0740] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Yuen CM, Millones AK, Galea JT, Puma D, Jimenez J, Lecca L, Becerra MC, Keshavjee S. Toward patient-centered tuberculosis preventive treatment: preferences for regimens and formulations in Lima, Peru. BMC Public Health 2021;21:121. [PMID: 33430823 DOI: 10.1186/s12889-020-10098-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Semitala FC, Musinguzi A, Ssemata J, Welishe F, Nabunje J, Kadota JL, Berger CA, Katamba A, Kiwanuka N, Kamya MR, Dowdy D, Cattamanchi A, Katahoire AR. Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives. Implement Sci Commun 2021;2:71. [PMID: 34193311 DOI: 10.1186/s43058-021-00173-2] [Reference Citation Analysis]
3 Hirsch-Moverman Y, Strauss M, George G, Mutiti A, Mafukidze A, Shongwe S, Dube GS, El Sadr WM, Mantell JE, Howard AA. Paediatric tuberculosis preventive treatment preferences among HIV-positive children, caregivers and healthcare providers in Eswatini: a discrete choice experiment. BMJ Open 2021;11:e048443. [PMID: 34686549 DOI: 10.1136/bmjopen-2020-048443] [Reference Citation Analysis]